Zynex Inc (ZYXIQ) — SEC Filings
Zynex Inc (ZYXIQ) — 28 SEC filings. Latest: 8-K (Dec 18, 2025). Includes 17 8-K, 5 10-Q, 2 DEF 14A.
Overview
Zynex Inc (ZYXIQ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 16, 2025: On December 15, 2025, Zynex, Inc. entered into a material definitive agreement. The company also reported triggering events that could accelerate or increase financial obligations, and made a Regulation FD disclosure. The filing includes financial statements and exhibits.
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 1 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Zynex Inc is neutral.
Filing Type Overview
Zynex Inc (ZYXIQ) has filed 17 8-K, 5 10-Q, 1 10-K/A, 2 DEF 14A, 2 10-K, 1 DEFA14A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of ZYXIQ's 27 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $62,228,000 |
| Net Income | $(73,300,000) |
| EPS | $(1.42) |
| Debt-to-Equity | N/A |
| Cash Position | $13,259,000 |
| Operating Margin | N/A |
| Total Assets | $45,322,000 |
| Total Debt | $86,694,000 |
Key Executives
- Patrick J. Reilly
- Dr. David L. Bear
- Mr. John R. Smith
- Mr. Sandgaard
Industry Context
The medical device and supplies industry is highly competitive and subject to stringent regulatory oversight. Companies often rely on innovation and market access to drive growth. Zynex operates in a niche focused on electrotherapy devices for pain management and patient monitoring, facing competition from larger players and specialized medical technology firms.
Top Tags
financials (5) · 10-Q (4) · financial-reporting (3) · corporate-governance (3) · Medical Devices (2) · leadership-change (2) · officer-appointment (2) · director-election (2) · compensation (2) · disclosure (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total net revenue for nine months ended Sept 30, 2025 | $62.2 million | a 57.5% decrease from $146.4 million in 2024 |
| Net loss for nine months ended Sept 30, 2025 | $(73.3) million | compared to $3.6 million net income in 2024 |
| Cash and cash equivalents as of Sept 30, 2025 | $13.3 million | a 66.5% decrease from $39.6 million at Dec 31, 2024 |
| Current portion of convertible senior notes | $59.3 million | maturing on May 15, 2026, significantly impacting current liabilities |
| Impairment charges | $30.7 million | primarily related to the Zynex Monitoring Solutions business |
| Workforce reduction in Q1 2025 | 15% | to align operating expenses with current revenue levels |
| Further workforce reduction in Q2 2025 | 14% | affecting 86 corporate roles |
| Revenue reduction related to Tricare payments | $2.8 million | during the quarter ended September 30, 2025, due to repayment demands |
| Historical Tricare revenue contribution | 20-25% | prior to the payment suspension |
| Basic net loss per share for Q3 2025 | $(1.42) | compared to $0.07 basic net income per share in Q3 2024 |
| Conformed Period of Report | 2024-12-31 | The fiscal year-end for the amended 10-K filing. |
| Filed As Of Date | 2025-07-24 | The date the 10-K/A was officially filed with the SEC. |
| Central Index Key (CIK) | 0000846475 | Unique identifier for ZYNEX INC with the SEC. |
| SEC File Number | 001-38804 | The SEC file number for ZYNEX INC. |
| Film Number | 251147870 | The film number associated with this specific SEC filing. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Zynex Inc (ZYXIQ)?
Zynex Inc has 28 recent SEC filings from Feb 2024 to Dec 2025, including 17 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ZYXIQ filings?
Across 28 filings, the sentiment breakdown is: 1 bearish, 26 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Zynex Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Zynex Inc (ZYXIQ) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Zynex Inc?
Key financial highlights from Zynex Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ZYXIQ?
The investment thesis for ZYXIQ includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Zynex Inc?
Key executives identified across Zynex Inc's filings include Patrick J. Reilly, Dr. David L. Bear, Mr. John R. Smith, Mr. Sandgaard.
What are the main risk factors for Zynex Inc stock?
Of ZYXIQ's 27 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Zynex Inc?
Forward guidance and predictions for Zynex Inc are extracted from SEC filings as they are enriched.